See more : Opendoor Technologies Inc. (OPEN) Income Statement Analysis – Financial Results
Complete financial analysis of Metacrine, Inc. (MTCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Metacrine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tiga Acquisition Corp. (TINV-UN) Income Statement Analysis – Financial Results
- YTO Express (International) Holdings Limited (6123.HK) Income Statement Analysis – Financial Results
- SCB X Public Company Limited (SCB-R.BK) Income Statement Analysis – Financial Results
- Electra Battery Materials Corporation (0UVX.L) Income Statement Analysis – Financial Results
- Crown International Corporation Limited (0727.HK) Income Statement Analysis – Financial Results
Metacrine, Inc. (MTCR)
About Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.45M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.45M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 45.47M | 26.79M | 25.97M | 22.94M |
| General & Administrative | 15.61M | 9.90M | 4.03M | 5.24M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 9.90M | 4.03M | 5.24M |
| Other Expenses | 0.00 | -614.00K | 0.00 | 0.00 |
| Operating Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Cost & Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Interest Income | 102.00K | 494.00K | 1.42M | 934.00K |
| Interest Expense | 1.20M | 1.01M | 347.00K | 0.00 |
| Depreciation & Amortization | 972.00K | 931.00K | 2.25M | 829.00K |
| EBITDA | -61.08M | -36.69M | -27.76M | -24.99M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,723.59% |
| Operating Income | -61.08M | -36.69M | -30.00M | -26.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,843.38% |
| Total Other Income/Expenses | -1.13M | -614.00K | 1.07M | 908.00K |
| Income Before Tax | -62.21M | -37.30M | -28.93M | -25.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| Income Tax Expense | -972.00K | -931.00K | 347.00K | 908.00K |
| Net Income | -61.24M | -36.37M | -29.28M | -25.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| EPS | -1.45 | -3.87 | -1.52 | -1.35 |
| EPS Diluted | -1.45 | -3.87 | -1.52 | -1.35 |
| Weighted Avg Shares Out | 42.11M | 9.40M | 19.22M | 19.06M |
| Weighted Avg Shares Out (Dil) | 42.11M | 9.40M | 19.22M | 19.06M |
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company's board of directors,...
U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week
The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in...
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and...
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief...
Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief...
3 Net-Net Working Capital Stocks
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value....
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology
Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA)...
Source: https://incomestatements.info
Category: Stock Reports